Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark. more
Time Frame | EVAX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17.4% | 0.31% | -1.26% |
1-Month Return | -28.02% | 0.6% | -4.16% |
3-Month Return | -71.9% | -9.44% | -0.46% |
6-Month Return | -76% | -5.15% | 3.58% |
1-Year Return | -90.49% | 0.33% | 22.47% |
3-Year Return | -98.15% | 4.53% | 25.13% |
5-Year Return | -99.24% | 35.98% | 77.7% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 73.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 80.98K | 105.72K | 343.45K | 571.32K | 112.00 | [{"date":"2019-12-31","value":14.17,"profit":true},{"date":"2020-12-31","value":18.5,"profit":true},{"date":"2021-12-31","value":60.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.02,"profit":true}] |
Gross Profit | (80.98K) | (105.72K) | (343.45K) | (571.32K) | 72.89K | [{"date":"2019-12-31","value":-111.11,"profit":false},{"date":"2020-12-31","value":-145.04,"profit":false},{"date":"2021-12-31","value":-471.21,"profit":false},{"date":"2022-12-31","value":-783.83,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | 99.85% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 10.86M | 16.57M | 25.83M | 25.26M | 22.25M | [{"date":"2019-12-31","value":42.05,"profit":true},{"date":"2020-12-31","value":64.13,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.79,"profit":true},{"date":"2023-12-31","value":86.11,"profit":true}] |
Operating Income | (10.86M) | (16.57M) | (25.83M) | (25.26M) | (22.20M) | [{"date":"2019-12-31","value":-1086300000,"profit":false},{"date":"2020-12-31","value":-1656800000,"profit":false},{"date":"2021-12-31","value":-2583400000,"profit":false},{"date":"2022-12-31","value":-2526400000,"profit":false},{"date":"2023-12-31","value":-2219700000,"profit":false}] |
Total Non-Operating Income/Expense | (2.37M) | (14.00K) | 2.25M | 2.65M | (3.73M) | [{"date":"2019-12-31","value":-89.57,"profit":false},{"date":"2020-12-31","value":-0.53,"profit":false},{"date":"2021-12-31","value":84.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-140.89,"profit":false}] |
Pre-Tax Income | (12.02M) | (16.57M) | (24.71M) | (23.94M) | (22.91M) | [{"date":"2019-12-31","value":-1202000000,"profit":false},{"date":"2020-12-31","value":-1657500000,"profit":false},{"date":"2021-12-31","value":-2471000000,"profit":false},{"date":"2022-12-31","value":-2394100000,"profit":false},{"date":"2023-12-31","value":-2291500000,"profit":false}] |
Income Taxes | (825.00K) | (1.56M) | (178.00K) | (772.00K) | (791.22K) | [{"date":"2019-12-31","value":-82500000,"profit":false},{"date":"2020-12-31","value":-155700000,"profit":false},{"date":"2021-12-31","value":-17800000,"profit":false},{"date":"2022-12-31","value":-77200000,"profit":false},{"date":"2023-12-31","value":-79121500,"profit":false}] |
Income After Taxes | (11.20M) | (15.02M) | (24.53M) | (23.17M) | (22.12M) | [{"date":"2019-12-31","value":-1119500000,"profit":false},{"date":"2020-12-31","value":-1501800000,"profit":false},{"date":"2021-12-31","value":-2453200000,"profit":false},{"date":"2022-12-31","value":-2316900000,"profit":false},{"date":"2023-12-31","value":-2212378500,"profit":false}] |
Income From Continuous Operations | (11.20M) | (15.02M) | (24.53M) | (23.17M) | (24.47M) | [{"date":"2019-12-31","value":-1119500000,"profit":false},{"date":"2020-12-31","value":-1501800000,"profit":false},{"date":"2021-12-31","value":-2453200000,"profit":false},{"date":"2022-12-31","value":-2316900000,"profit":false},{"date":"2023-12-31","value":-2447400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (11.20M) | (15.02M) | (24.53M) | (23.17M) | (22.13M) | [{"date":"2019-12-31","value":-1119500000,"profit":false},{"date":"2020-12-31","value":-1501800000,"profit":false},{"date":"2021-12-31","value":-2453200000,"profit":false},{"date":"2022-12-31","value":-2316900000,"profit":false},{"date":"2023-12-31","value":-2212500000,"profit":false}] |
EPS (Diluted) | - | (0.19) | (1.25) | (3.59) | (2.26) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-19,"profit":false},{"date":"2021-12-31","value":-125,"profit":false},{"date":"2022-12-31","value":-359,"profit":false},{"date":"2023-12-31","value":-226,"profit":false}] |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
EVAX | |
---|---|
ROA (LTM) | -69.45% |
ROE (LTM) | -802.80% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
EVAX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.00 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.00 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
EVAX | |
---|---|
Trailing PE | NM |
Forward PE | 3.57 |
P/S (TTM) | 1.51 |
P/B | 336.90 |
EV/R | 8.32 |
EV/Ebitda | NM |
Evaxion Biotech AS (EVAX) share price today is $3.7791
Yes, Indians can buy shares of Evaxion Biotech AS (EVAX) on Vested. To buy Evaxion Biotech AS from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EVAX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Evaxion Biotech AS (EVAX) via the Vested app. You can start investing in Evaxion Biotech AS (EVAX) with a minimum investment of $1.
You can invest in shares of Evaxion Biotech AS (EVAX) via Vested in three simple steps:
The 52-week high price of Evaxion Biotech AS (EVAX) is $68.05. The 52-week low price of Evaxion Biotech AS (EVAX) is $3.32.
The price-to-earnings (P/E) ratio of Evaxion Biotech AS (EVAX) is
The price-to-book (P/B) ratio of Evaxion Biotech AS (EVAX) is 336.90
The dividend yield of Evaxion Biotech AS (EVAX) is 0.00%
The market capitalization of Evaxion Biotech AS (EVAX) is $22.17M
The stock symbol (or ticker) of Evaxion Biotech AS is EVAX